SCOLR Pharma has entered into a research collaboration with a U.S.-based biopharma company to develop an oral formulation of a promising antiviral compound using its proprietary CDT® drug delivery platform. The compound under development has the potential to be used as a treatment against influenza. The goal of the program is to enhance the bioavailability of the compound to facilitate oral administration. If successful, the parties expect to enter a license agreement, which would provide for th...